Update from Teladoc Health Inc. (TDOC): A steady trajectory

Teladoc Health Inc. (NYSE: TDOC) closed the day trading at $27.66 up 5.65% from the previous closing price of $26.18. In other words, the price has increased by $+1.48 from its previous closing price. On the day, 4126137 shares were traded. TDOC stock price reached its highest trading level at $27.84 during the session, while it also had its lowest trading level at $25.97.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…



For a better understanding of TDOC, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.74 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 22.01. For the most recent quarter (mrq), Quick Ratio is recorded 3.00 and its Current Ratio is at 3.10. In the meantime, Its Debt-to-Equity ratio is 0.26 whereas as Long-Term Debt/Eq ratio is at 0.25.

Upgrades & Downgrades

On September 07, 2022, Truist started tracking the stock assigning a Hold rating and target price of $35.Truist initiated its Hold rating on September 07, 2022, with a $35 target price.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 17 when Trencher Daniel sold 1,000 shares for $26.80 per share. The transaction valued at 26,800 led to the insider holds 21,408 shares of the business.

Trencher Daniel sold 1,000 shares of TDOC for $26,930 on Dec 19. The SVP CORPORATE STRATEGY now owns 22,408 shares after completing the transaction at $26.93 per share. On Dec 01, another insider, Jensen Claus Torp, who serves as the CHIEF INNOVATION OFFICER of the company, sold 1,783 shares for $28.86 each. As a result, the insider received 51,457 and left with 1,782 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 1.84 while its Price-to-Book (P/B) ratio in mrq is 0.74.

Stock Price History:

Over the past 52 weeks, TDOC has reached a high of $80.83, while it has fallen to a 52-week low of $21.60. The 50-Day Moving Average of the stock is 26.76, while the 200-Day Moving Average is calculated to be 33.75.

Shares Statistics:

Over the past 3-months, TDOC traded about 4.65M shares per day on average, while over the past 10 days, TDOC traded about 4.8M shares per day. A total of 161.73M shares are outstanding, with a floating share count of 160.19M. Insiders hold about 0.10% of the company’s shares, while institutions hold 83.80% stake in the company. Shares short for TDOC as of Oct 13, 2022 were 33.08M with a Short Ratio of 28.52M, compared to 32.12M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 20.47% and a Short% of Float of 23.33%.

Earnings Estimates

Current recommendations for the stock of the company come from 20 analysts. On average, analysts expect EPS of -$0.25 for the current quarter, with a high estimate of -$0.09 and a low estimate of -$0.65, while EPS last year was -$0.07. The consensus estimate for the next quarter is -$0.41, with high estimates of -$0.19 and low estimates of -$0.62.

Analysts are recommending an EPS of between -$1.59 and -$61.65 for the fiscal current year, implying an average EPS of -$58.74. EPS for the following year is -$1.44, with 24 analysts recommending between -$0.83 and -$2.31.

Revenue Estimates

25 analysts predict $632.59M in revenue for the current quarter. It ranges from a high estimate of $656.99M to a low estimate of $623M. As of the current estimate, Teladoc Health Inc.’s year-ago sales were $554.24M, an estimated increase of 14.10% from the year-ago figure. For the next quarter, 18 analysts are estimating revenue of $655.94M, an increase of 15.30% over than the figure of $14.10% in the same quarter last year. There is a high estimate of $672.47M for the next quarter, whereas the lowest estimate is $641.7M.

A total of 29 analysts have provided revenue estimates for TDOC’s current fiscal year. The highest revenue estimate was $2.43B, while the lowest revenue estimate was $2.39B, resulting in an average revenue estimate of $2.4B. In the same quarter a year ago, actual revenue was $2.03B, up 18.20% from the average estimate. Based on 29 analysts’ estimates, the company’s revenue will be $2.74B in the next fiscal year. The high estimate is $2.9B and the low estimate is $2.65B. The average revenue growth estimate for next year is up 14.20% from the average revenue estimate for this year.